Marisa Wexler, MS, senior science writer —

While people with multiple sclerosis (MS) taking anti-CD20 therapies do not mount a robust antibody response after getting vaccinated against COVID-19, the vaccines do strongly activate other parts of the immune system that are likely to be helpful in fighting the virus, a new study shows. “The message…

An imaging feature called a rim lesion is found in about 4 out of every 10 people with multiple sclerosis (MS), according to a review study. These rims, thought to represent areas of chronic brain inflammation in which myelin is being progressively damaged, may serve as alternate biomarkers of…

A class of molecules called positive allosteric modulators, or PAMs, may be useful in treating pain caused by nerve damage — a common symptom of multiple sclerosis (MS) — according to a new study that sheds light on how these molecules work. The international team of researchers behind…

An interaction between immune cells and glia cells in the brain, mediated by the C1q complement system protein, appears to drive chronic inflammation in multiple sclerosis (MS), new research shows. Inhibiting this protein helped to resolve inflammation in mouse models of MS and in tissue cultures, its researchers found.

Getting the Pfizer-BioNTech vaccine for COVID-19 does not increase the risk of multiple sclerosis (MS) relapses in the two months following vaccination, according to a new study. The results support recommending COVID-19 vaccines for people with MS, its researchers said. “The incidence of relapses in the 2 months before…

Experiencing serious infections during adolescence is tied to an increased risk of developing multiple sclerosis (MS) later in life, but those occurring in childhood don’t increase MS risk, according to a new Swedish study. The study also found that certain types of infections, especially those that affect the central…

People with relapsing-remitting multiple sclerosis (RRMS) in Sweden have lower rates of worsening disability than those who live in Denmark, likely due to differences in treatment strategies in each country, according to a new study. “This study shows that, for the first time to our knowledge, differences in national…

Most people with multiple sclerosis (MS) in the U.S. have health insurance, but many lack important other types of insurance, such as life insurance, short-term disability insurance, and long-term care insurance, according to an online survey of patients. Its findings suggest that MS patients who are likely to be…

A new research project, funded by the National Institutes of Health (NIH), aims to better understand how different types of cells in the nervous system — specifically neurons and glia cells — communicate with each other and ultimately affect both motor and non-motor functions. Its findings may have important implications…

A variation in a gene called STK11, previously shown to increase the risk for multiple sclerosis (MS) among Caucasians, is now also linked to a greater likelihood of MS in Black people. In fact, the variation was significantly more common in Black MS patients with secondary progressive MS (SPMS),…

PoNS, a non-invasive devise to accompany physical therapy in multiple sclerosis (MS) patients with difficulty walking, will be available on the U.S. market early next year, its developer, Helius Medical Technologies, announced in a quarterly financial update. Short for Portable Neuromodulation Stimulator, the PoNS…

A smartphone-based app called Floodlight can reliably assess cognition, arm and hand function, and walking abilities in people with multiple sclerosis (MS), according to new analyses. “Detection of progression onset or worsening is critical to optimally adapt the therapeutic strategy” patients are using to treat the neurodegenerative disease,…

A Phase 3 clinical trial testing the effect of Ocrevus (ocrelizumab) on upper limb disability progression in people with primary progressive multiple sclerosis (PPMS) is recruiting participants. The trial, called O’HAND (NCT04035005), expects to enroll approximately 1,000 adults with PPMS, ages 18 to 65, at more than…

Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according to an analysis of four randomized clinical trials. Physicians working with these patients might recommend “confirmed probiotic supplements” to help manage “MS concerns,” its scientists wrote, while noting that studies…

Lemtrada (alemtuzumab) does not have a substantial effect on blood pressure or platelet counts, and does not lead to bleeding in the brain of multiple sclerosis (MS) patients, according to a small Belgian study. The findings contrast with previous studies showing an increase in blood pressure, stroke, and…

Visits to the hospital related to multiple sclerosis (MS) are more common when it’s hot or when temperatures are more variable, but less likely to be needed when it’s humid, a new analysis suggests. The results were published in the International Journal of Environmental Research and Public Health, in…

More than half of people with multiple sclerosis (MS) who require an informal caregiver have experienced abuse or mistreatment by that caregiver, according to a study conducted in California. The study, “Validity and Reliability of the Scale to Report Emotional Stress Signs–Multiple Sclerosis (STRESS-MS) in Assessing…

More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with their quality of life, and more than one in four MS patients are pessimistic about their future, according to the results of the survey, conducted by Multiple Sclerosis News…

Treatment with the diabetes medication metformin was seen to lessen cognitive impairment, improve coordination, and normalize neuronal activity in a rat model of multiple sclerosis (MS). The study reporting these findings, “Evaluation of the effects of metformin as adenosine monophosphate-activated protein kinase activator on spatial learning and…

A signaling protein called fractalkine helps to regulate the development of oligodendrocytes, cells of the nervous system responsible for making myelin — the protecting coating of nerve cell fibers that is damaged and lost in multiple sclerosis (MS). This finding was in the study, “Fractalkine signaling regulates…

Subtle changes in structure in the hippocampus — a region of the brain involved in processing memories — can differentiate between relapsing-remitting and primary progressive multiple sclerosis, according to a new study. The study, “Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and Relapsing–Remitting Multiple Sclerosis Phenotypes,”…

People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in their disease in recent years, compared to individuals who switched to the treatment around the time it became available, a new study indicates. The findings suggest “an increased experience in…

NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to…

Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of multiple sclerosis (MS), a new study reports. The findings imply that B-cells — the immune cells that are killed by anti-CD20 antibodies — play a central role in the…

The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medication IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…

In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below the 0.1 threshold among patients with relapsing forms of multiple sclerosis (MS), while improving disability outcomes in a significant proportion of patients. “The [relapse] rate was below a tenth…

Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…

Many people with multiple sclerosis (MS) start experiencing symptoms of the disease several years before being diagnosed, a new study suggests. While it has long been known that people with MS tend to seek medical attention more frequently in the years before diagnosis than those without the disease, there…

Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing them to retain an ability to fight infections, new data from a Phase 3 clinical trial indicate. “These long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with…

The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS). Aubagio, approved for adults with RRMS since 2013, is now the first oral therapy available as a first-line treatment for pediatric patients in the European…